Sulfonylurea K ATP Blockade in Type II Diabetes and Preconditioning in Cardiovascular Disease-Reference-Cited by-同舟云学术

Sulfonylurea K ATP Blockade in Type II Diabetes and Preconditioning in Cardiovascular Disease

Published:1996-11 Issue:9 Volume:94 Page:2297-2301
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Engler Robert L.¹,Yellon Derek M.¹

Affiliation:

1. the Division of Cardiology, Department of Medicine, Department of Veterans Affairs Medical Center, San Diego, and University of California, San Diego, School of Medicine, La Jolla (R.L.E.), and the Division of Cardiology, Hatter Institute, University College London Medical School, UK (D.M.Y.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference66 articles.

1. The University Group Diabetes Program

2. The University Group Diabetes Program

3. A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP)

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review;Diabetes Therapy;2024-06-27

2. Lada or Type 2 Diabetes Mellitus - A Challenging Diagnosis in Clinical Approach;Acta Medica Transilvanica;2021-09-01

3. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms;Cardiovascular Research;2021-08-15

4. Methylome-wide association study provides evidence of particulate matter air pollution-associated DNA methylation;Environment International;2019-11

5. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial;BMC Cardiovascular Disorders;2019-03-15